Microbot Medical (NASDAQ:MBOT) Downgraded to Sell Rating by Wall Street Zen

Key Points

• Microbot Medical has been downgraded from a "hold" rating to a "sell" rating by Wall Street Zen, raising concerns among investors.
• Despite the downgrade, HC Wainwright has reaffirmed a "buy" rating with a target price of $12.00 for the stock, indicating mixed analyst sentiments.
• Recently, Microbot Medical reported earnings of ($0.10) EPS, which was below analysts' expectations of ($0.08), reflecting potential challenges in its financial performance.

Microbot Medical (NASDAQ:MBOT - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Several other research firms have also recently commented on MBOT. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 target price on shares of Microbot Medical in a research report on Wednesday, October 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Microbot Medical in a report on Wednesday, October 8th. Finally, Zacks Research cut Microbot Medical from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $12.00.

Microbot Medical Stock Performance

Shares of MBOT stock opened at $2.42 on Friday. Microbot Medical has a fifty-two week low of $0.89 and a fifty-two week high of $4.67. The firm has a market cap of $162.53 million, a P/E ratio of -4.17 and a beta of 1.25. The business's 50 day moving average price is $3.33 and its 200-day moving average price is $2.82.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.02). As a group, equities analysts predict that Microbot Medical will post -0.71 EPS for the current year.

Institutional Trading of Microbot Medical

Several institutional investors have recently bought and sold shares of the company. U.S. Capital Wealth Advisors LLC bought a new stake in Microbot Medical during the 2nd quarter valued at about $25,000. American Century Companies Inc. bought a new stake in shares of Microbot Medical during the second quarter valued at approximately $32,000. SLT Holdings LLC purchased a new position in Microbot Medical in the 3rd quarter worth approximately $38,000. Beacon Capital Management LLC lifted its position in Microbot Medical by 166.7% in the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Microbot Medical in the 1st quarter valued at approximately $42,000. 16.30% of the stock is owned by hedge funds and other institutional investors.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.